

Biomarkers for Brain Disorders: Challenges and Opportunities

Sunday 1- Tuesday 3 February 2015

Wellcome Trust Genome Campus, Hinxton, Cambridge, UK

Draft programme

Posters will be on display throughout the meeting

Sunday 1 February 2015

12:00-13:00 Registration and Buffet Lunch

13:15 Welcome and Introduction
Andreas Jeromin, Quanterix Inc., USA

Session 1: Brain Biomarkers – Challenges and Opportunities
Chair: Andreas Jeromin, Quanterix Inc., USA

13:30 Keynote Presentation
Title to be confirmed
Mark Schmidt, Janssen, Belgium

14:30 Title to be confirmed
Alessandro Bertolino, Roche, Switzerland

15:00 Large, clinical population-based studies as sources for big datasets
Simon Lovestone, King's College London, UK

15:30 Afternoon tea
EBI-South Foyer

16:00 Harmonisation and standardisation of biobanking and biomarker measurement
Charlotte Teunissen, VU University Medical Centre, The Netherlands

16:30 Standardisation of MRI measures of cerebrovascular disease
Joanna Wardlaw, University of Edinburgh, UK

17:00 Biomarkers in AD – Regulatory point of view
Maria Isaac, European Medicines Agency, UK

17:30 Molecular biomarkers of neurodegenerative disease in the olfactory epithelium
Gabriela Gurria, Wellcome Trust Sanger Institute, UK

17:45	Standardisation, big data and global knowledge exchange in metabolomics: an opportunity for brain biomarker research Reza Salek , EMBL-EBI, UK
18.00	Session Summary/Discussion
18.30	Welcome drinks reception
19:00	Dinner with cash bar (in Hinxton Hall)

Monday 2 February 2015

07.30 Breakfast

Session 2: Prodromal Biomarkers

Chair: Brit Mollenhauer University of Gottingen, Germany

08.30 The European Medical Information Framework on Alzheimer's disease
Pieter Jelle Visser, Maastricht University, The Netherlands

09.00 Identification of prodromal biomarkers in AD-the NewMeds Initiative
Jill Richardson, GSK, UK

09.30 talk title tbc
Kenneth Marek, Molecular NeuroImaging, USA

10:00 Morning Coffee
EBI- South Foyer

10.30 Non-motor symptoms and other candidates as prodromal biomarkers for Parkinson's disease
Brit Mollenhauer, University of Gottingen, Germany

11:00 Large-clinical population-based studies as sources for big datasets: CFAS
Carol Brayne, University of Cambridge, UK

11:30 Blood-based markers of Alzheimer's pathology and early cognitive decline: potential for enrichment of preventional trials?
Steven Kiddie, King's College London, UK

11:45 A functional biomarker to understand the earliest pathological pathways in Parkinson's disease
Amy Smith, University of Oxford, UK

12:00 Session summary/Discussion
12.30 Lunch
EBI- South Foyer

Session 3 Heterogeneity in Neurodegenerative Diseases

Chair: William Potter NIH, USA

Provisional Programme v20

Wellcome Trust Scientific Conferences

13.30	Vascular factors in neurodegeneration Geert Jan Biessels , <i>University of Utrecht, The Netherlands</i>
14:00	Cognitively healthy centenarians – key to finding treatment for Alzheimer's? Henne Holstege , <i>VU University Medical Centre, The Netherlands</i>
14:30	Arterial spin labeling reveals differences in perfusion and cerebrovascular reserve in a mouse model for Alzheimer's disease Kristof Govaerts , <i>KU Leuven, Belgium</i>
14:45	Genetic influences on metabolite levels in Alzheimer's disease Petroula Proitsi , <i>King's College London, UK</i>
15.00	Afternoon Tea <i>EBI-South Foyer</i>
15:30	Additional neurological diseases Mark Allegretta , <i>National Multiple Sclerosis Society, USA</i>
16:00	Identification and replication of biomarkers of Alzheimer's disease in blood samples from different cohorts Aurelie Boucard , <i>PHARNEXT, France</i>
16:15-16.45	Session Summary/Discussion/Introduction to workshops
17.00	Workshops
	Group 1: Cognition/functional biomarkers Facilitators: Brit Mollenhauer and Maria Isaac
	Group 2: Big data and biomarkers: the need for standards Facilitators: Andreas Jeromin and Pieter Jelle Visser
	Group 3: A critical appraisal of current biomarkers Facilitators: Andy Lockhart and Agneta Nordberg
18:30	Poster session with drinks reception (Chestnut suite, Hinxton Hall) <i>18.30-19.15 (odd numbers); 19.15-20.00 (even numbers)</i>
20:00	Conference Dinner

Tuesday 3 February 2015

07.30	Breakfast
08:30	Workshops contd. Summary of break-out-sessions from group facilitators Maria Isaac, Pieter Jelle Visser and Agneta Nordberg
Session 4	Imaging and Early Diagnosis <i>Chair: Wiesje van der Flier</i> VU University Medical Center, The Netherlands

09:15 Tau imaging
Bart van Berckel, VU University Medical Centre, The Netherlands

09.45 Standardization of neuroimaging techniques
Derek Hill, IXICO, UK

10:15 Impact of amyloid imaging on early diagnosis and clinical trials
Agneta Nordberg, Karolinska Institutet, Sweden

10:45 Morning Coffee
EBI-South Foyer

11:15 Blood protein markers of neocortical amyloid burden: a candidate study using SOMAscan technology
Nicola Voyle, King's College London, UK

11:30 The use of polygenic risk scores for predicting the rate of cognitive decline in Alzheimer's disease
Elizabeth Baker, King's College London, UK

11.45 Biomarkers for disorders of consciousness
Laurent Hermoye, Imagilys, Belgium

12:00 Session Summary/Discussion

12.30 Lunch
EBI-South Foyer

Session 5 Traumatic Brain Injury and Stroke

Chair: Andy Lockhart GlaxoSmithKline, UK

13:15 Developing and implementing biomarkers for precision medicine approaches in traumatic brain injury
David Menon, University of Cambridge, UK

13:45 Are we ready to use stroke biomarkers?"
Joan Montaner, Vall Hebron Research Institute, Spain

14:15 Blood transcriptome changes after stroke: a next-generation sequencing study in an African-American population
Robert Meller, Morehouse School of Medicine, USA

14.30 Session summary and conference wrap-up

15:00 Conference closes